FDA Issues Revised Guidance on QT Interval Prolongation
New regulatory updates clarify clinical and nonclinical evaluation of potential proarrhythmic drug risks.
Updated on Oct. 30, 2026 in Heart Disease
The Food and Drug Administration has released updated guidance for evaluating QT and QTc interval prolongation, which are critical indicators of drug safety. The new document provides clarifications on questions related to both clinical and nonclinical research protocols.
Why it matters
This updated guidance aims to streamline the implementation of industry safety standards for pharmaceutical developers. By clarifying testing requirements, the FDA helps ensure that potential cardiac side effects are identified more efficiently during drug evaluation.
The updated document modifies questions 5.1, 6.1, and 6.3 for the E14 guidance while adding new inquiry sections for S7B. These updates represent the latest refinement to the original ICH standards established in October 2005.
The players
Food and Drug Administration
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs, biological products, and medical devices.
The details
The agency released the revised E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential Questions and Answers (R1) to assist the industry. It integrates new questions for sections 1 and 3 of the S7B guidance to improve clarity for researchers and manufacturers.
Timeline
October 2005: Original ICH E14 and S7B guidances were published.
October 30, 2026: Revised Q&A guidance for industry was published.
Health Landscape
This release updates the foundational ICH E14 and S7B guidelines to reflect current scientific standards. These protocols are essential for monitoring cardiac safety and ensuring that potential risks are managed effectively within the broader healthcare system.
By refining the evaluation of potential cardiac drug risks, these updates contribute to more robust safety protocols for medications entering the market. Patients can expect improved regulatory oversight that reduces the likelihood of adverse cardiac effects from new treatments.
The takeaway
The FDA’s updated guidance provides essential clarity for manufacturers navigating complex cardiac safety evaluations. Developers should integrate these revised Q&A clarifications into their ongoing clinical and nonclinical assessment workflows.
Further reading
Learn more about cardiovascular safety standards on our Heart Disease section page.
More information
Review the full details in the FDA guidance document page.
Source note: This article includes information reported by U.S. Food and Drug Administration.
